Guardant Health Gross Profit 2017-2022 | GH

Guardant Health gross profit from 2017 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Guardant Health Annual Gross Profit
(Millions of US $)
2021 $251
2020 $194
2019 $144
2018 $47
2017 $18
2016 $3
Guardant Health Quarterly Gross Profit
(Millions of US $)
2022-03-31 $64
2021-12-31 $75
2021-09-30 $64
2021-06-30 $62
2021-03-31 $50
2020-12-31 $50
2020-09-30 $53
2020-06-30 $44
2020-03-31 $47
2019-12-31 $41
2019-09-30 $42
2019-06-30 $37
2019-03-31 $23
2018-12-31 $19
2018-09-30 $12
2018-06-30 $9
2018-03-31 $7
2017-12-31
2017-09-30 $2
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.926B $0.374B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00